title: Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells.
abstract: Cleaved high molecular weight kininogen (HKa) has been shown to inhibit in vivo neovascularization and induce apoptosis of endothelial cells. We have shown that HKa-induced apoptosis correlated with its antiadhesive effect and was regulated by extracellular matrix (ECM) proteins. In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as a target of HKa activity at the endothelial cell surface. Anti-uPAR antibodies blocked the apoptotic effect of HKa. Further studies revealed that uPAR formed a signaling complex containing integrin alpha(v)beta3 or alpha5beta1, caveolin, and Src kinase Yes in endothelial cells. HKa physically disrupted the formation of this complex in a manner that paralleled its apoptotic effect. For the first time, our results provide a mechanistic explanation for the previous observation that HKa selectively induces apoptosis of endothelial cells grown on vitronectin, but not cells grown on fibronectin. These data also resolve the controversial role of uPAR in mediating the apoptotic and antiadhesive activities of HKa.
authors.affiliation: Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pa 19140, USA.
authors.forename: Dian J
authors.initials: DJ
authors.lastname: Cao
authors.forename: Yan-Lin
authors.initials: YL
authors.lastname: Guo
authors.forename: Robert W
authors.initials: RW
authors.lastname: Colman
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D051242:Caveolin 1; D022461:Caveolins / Q000502:physiology; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D042783:Endothelial Cells; D004730:Endothelium, Vascular; D016326:Extracellular Matrix Proteins / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005353:Fibronectins / Q000494:pharmacology; D006801:Humans; D039081:Integrin alpha5beta1 / Q000502:physiology; D039302:Integrin alphaVbeta3 / Q000502:physiology; D019679:Kininogen, High-Molecular-Weight / Q000494:pharmacology / Q000502:physiology*; D046911:Macromolecular Substances; D043265:Phosphatidylinositol Diacylglycerol-Lyase / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000502:physiology; D051575:Proto-Oncogene Proteins c-yes; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology*; D055293:Receptors, Urokinase Plasminogen Activator; D014471:Umbilical Veins; D019096:Vitronectin / Q000494:pharmacology; D019061:src-Family Kinases
chemical_list: D000911:Antibodies, Monoclonal; C495540:CAV1 protein, human; D051242:Caveolin 1; D022461:Caveolins; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D039081:Integrin alpha5beta1; D039302:Integrin alphaVbeta3; D019679:Kininogen, High-Molecular-Weight; D046911:Macromolecular Substances; C524898:PLAUR protein, human; D011518:Proto-Oncogene Proteins; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D019096:Vitronectin; D016222:Fibroblast Growth Factor 2; D011505:Protein-Tyrosine Kinases; D051575:Proto-Oncogene Proteins c-yes; D019061:src-Family Kinases; D043265:Phosphatidylinositol Diacylglycerol-Lyase